Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Brian Matthew Wolpin, M.D.

Co-Author

This page shows the publications co-authored by Brian Wolpin and Kimmie Ng.
Connection Strength

6.644
  1. Unrestrained eating behavior and risk of digestive system cancers: a prospective cohort study. Am J Clin Nutr. 2021 Jul 22.
    View in: PubMed
    Score: 0.246
  2. FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discov. 2021 Oct; 11(10):2488-2505.
    View in: PubMed
    Score: 0.242
  3. Preexisting Type 2 Diabetes and Survival among Patients with Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2021 04; 30(4):757-764.
    View in: PubMed
    Score: 0.238
  4. Diabetes, Weight Change, and Pancreatic Cancer Risk. JAMA Oncol. 2020 10 01; 6(10):e202948.
    View in: PubMed
    Score: 0.233
  5. Prediagnostic Circulating Concentrations of Vitamin D Binding Protein and Survival among Patients with Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2020 11; 29(11):2323-2331.
    View in: PubMed
    Score: 0.232
  6. Acid-suppressive medications and risk of colorectal cancer: results from three large prospective cohort studies. Br J Cancer. 2020 09; 123(5):844-851.
    View in: PubMed
    Score: 0.228
  7. Postdiagnosis Loss of Skeletal Muscle, but Not Adipose Tissue, Is Associated with Shorter Survival of Patients with Advanced Pancreatic Cancer. Cancer Epidemiol Biomarkers Prev. 2019 12; 28(12):2062-2069.
    View in: PubMed
    Score: 0.217
  8. Prediagnostic Leukocyte Telomere Length and Pancreatic Cancer Survival. Cancer Epidemiol Biomarkers Prev. 2019 11; 28(11):1868-1875.
    View in: PubMed
    Score: 0.215
  9. Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer. Cancer Causes Control. 2019 Jul; 30(7):757-765.
    View in: PubMed
    Score: 0.212
  10. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial. JAMA. 2019 04 09; 321(14):1370-1379.
    View in: PubMed
    Score: 0.210
  11. Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. Br J Cancer. 2019 04; 120(8):848-854.
    View in: PubMed
    Score: 0.209
  12. Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). J Natl Cancer Inst. 2019 02 01; 111(2):170-179.
    View in: PubMed
    Score: 0.207
  13. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111.
    View in: PubMed
    Score: 0.199
  14. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol. 2018 Mar 08; 4(3):e173420.
    View in: PubMed
    Score: 0.195
  15. Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol. 2018 08; 16(8):1300-1306.e3.
    View in: PubMed
    Score: 0.194
  16. Statin use and pancreatic cancer risk in two prospective cohort studies. J Gastroenterol. 2018 Aug; 53(8):959-966.
    View in: PubMed
    Score: 0.193
  17. Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studies. Gastroenterology. 2018 04; 154(5):1380-1390.e5.
    View in: PubMed
    Score: 0.192
  18. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Br J Cancer. 2017 Dec 05; 117(12):1874-1882.
    View in: PubMed
    Score: 0.189
  19. Influence of dietary insulin scores on survival in colorectal cancer patients. Br J Cancer. 2017 Sep 26; 117(7):1079-1087.
    View in: PubMed
    Score: 0.187
  20. Cigarette Smoking and Pancreatic Cancer Survival. J Clin Oncol. 2017 Jun 01; 35(16):1822-1828.
    View in: PubMed
    Score: 0.183
  21. Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. Cancer Res. 2016 12 15; 76(24):7160-7167.
    View in: PubMed
    Score: 0.177
  22. Leucocyte telomere length, genetic variants at the TERT gene region and risk of pancreatic cancer. Gut. 2017 06; 66(6):1116-1122.
    View in: PubMed
    Score: 0.177
  23. Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. J Clin Oncol. 2016 08 20; 34(24):2899-905.
    View in: PubMed
    Score: 0.173
  24. Circulating Metabolites and Survival Among Patients With Pancreatic Cancer. J Natl Cancer Inst. 2016 Jun; 108(6):djv409.
    View in: PubMed
    Score: 0.168
  25. Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. J Clin Oncol. 2015 Jan 01; 33(1):29-35.
    View in: PubMed
    Score: 0.155
  26. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2014 Jun; 19(6):637-8.
    View in: PubMed
    Score: 0.150
  27. Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol. 2013 Nov 20; 31(33):4229-34.
    View in: PubMed
    Score: 0.144
  28. Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. Oncologist. 2013; 18(4):377-8.
    View in: PubMed
    Score: 0.139
  29. Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Invest New Drugs. 2014 Feb; 32(1):113-22.
    View in: PubMed
    Score: 0.139
  30. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2012 Jan; 21(1):82-91.
    View in: PubMed
    Score: 0.126
  31. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol. 2009 Jan 10; 27(2):176-85.
    View in: PubMed
    Score: 0.103
  32. Prediagnostic plasma folate and the risk of death in patients with colorectal cancer. J Clin Oncol. 2008 Jul 01; 26(19):3222-8.
    View in: PubMed
    Score: 0.100
  33. Prediagnostic Inflammation and Pancreatic Cancer Survival. J Natl Cancer Inst. 2021 Sep 04; 113(9):1186-1193.
    View in: PubMed
    Score: 0.062
  34. Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Cancer Res. 2021 06 01; 81(11):3134-3143.
    View in: PubMed
    Score: 0.060
  35. Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. Clin Cancer Res. 2021 03 15; 27(6):1695-1705.
    View in: PubMed
    Score: 0.059
  36. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Gastroenterology. 2021 03; 160(4):1373-1383.e6.
    View in: PubMed
    Score: 0.059
  37. A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. J Natl Cancer Inst. 2020 10 01; 112(10):1003-1012.
    View in: PubMed
    Score: 0.058
  38. Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Cancer Res. 2020 09 15; 80(18):4004-4013.
    View in: PubMed
    Score: 0.057
  39. Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Cancer Epidemiol Biomarkers Prev. 2020 09; 29(9):1784-1791.
    View in: PubMed
    Score: 0.057
  40. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2020 08; 29(8):1586-1595.
    View in: PubMed
    Score: 0.057
  41. Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. Cancer Epidemiol Biomarkers Prev. 2020 05; 29(5):999-1008.
    View in: PubMed
    Score: 0.056
  42. A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer. Invest New Drugs. 2020 10; 38(5):1533-1539.
    View in: PubMed
    Score: 0.055
  43. Feasibility of computer-based self-administered cancer-specific geriatric assessment in older patients with gastrointestinal malignancy. Oncologist. 2013; 18(1):64-72.
    View in: PubMed
    Score: 0.034
  44. A phase 2 study of oral MKC-1, an inhibitor of importin-ß, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Invest New Drugs. 2012 Aug; 30(4):1614-20.
    View in: PubMed
    Score: 0.031
  45. Interaction of molecular markers and physical activity on mortality in patients with colon cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5931-6.
    View in: PubMed
    Score: 0.027
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.